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Tumour growth depends on angiogenesis, which is closely associated with vascular endothelial growth factor (VEGF) and matrix
metalloproteinases (MMPs). Extracellular MMP inducer (EMMPRIN) was reported to involve in the progression of malignancies by
regulating expression of VEGF and MMPs in stromal cells. To clarify the role of EMMPRIN in progression and angiogenesis of gastric
carcinoma, expression of EMMPRIN, ki-67, MMP-2, MMP-9 and VEGF was examined on tissue microarray containing gastric
carcinomas (n¼234) and non-cancerous mucosa adjacent to carcinoma (n¼85) by immunohistochemistry. Additionally,
microvessel density (MVD) was assessed after labelling with anti-CD34 antibody. Extracellular MMP inducer expression was
compared with clinicopathological parameters of tumours, including levels of ki-67, MMP-2, MMP-9 and vascular endothelial growth
factor (VEGF), MVD as well as survival time of carcinoma patients. Gastric carcinoma cell lines (HGC-27, MKN28 and MKN45) were
studied for EMMPRIN expression by immunohistochemistry and Western blot. Extracellular MMP inducer expression was gradually
increased from normal mucosa to carcinomas through hyperplastic or metaplastic mucosa of the stomach (Po0.05). There was
strong EMMPRIN expression in all gastric carcinoma cell lines despite different levels of glycosylation. Extracellular MMP inducer
expression was positively correlated with tumour size, depth of invasion, lymphatic invasion, expression of ki-67, MMP-2, MMP-9 and
VEGF of tumours (Po0.05), but not with lymph node metastasis, UICC staging or differentiation (P40.05). Interestingly, there was a
significantly positive relationship between EMMPRIN expression and MVD in gastric carcinomas (Po0.05). Survival analysis indicated
EMMPRIN expression to be negatively linked to favourable prognosis (Po0.05), but not be independent factor for prognosis
(P40.05). Further analysis showed three independent prognostic factors, depth of invasion, lymphatic and venous invasion, to
influence the relationship between EMMPRIN expression and prognosis. Upregulated expression of EMMPRIN possibly contributes
to genesis, growth and local invasion of gastric carcinomas. Altered EMMPRIN expression might enhance growth, invasion and
angiogenesis of gastric carcinoma via upregulating MMP expression of both stromal fibroblasts and gastric cancer cells and could be
considered as an objective and effective marker to predict invasion and prognosis.
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Growth of solid tumours depends on angiogenesis, a complex and
multistep process which facilitates metastasis formation by
increasing the likelihood of tumour cells to enter the blood
circulation, provides nutrients and oxygen for growth at the
metastasis site (Rundhaug, 2005). Critical steps during tumour
angiogenesis are the outgrowth of endothelial cells from pre-
existing capillary vessel and their migration from parental vessels
under the stimulation of vascular endothelial growth factor
(VEGF). Proliferating endothelial cells subsequently remodel the
extracellular matrix (ECM) via matrix metalloproteinases (MMPs),
align into tube-like structures, and eventually form new functional
blood vessels. In cancer cells, overexpression of angiogenetic
factors (eg, VEGF, MMPs, etc.) results in their more secretion into
the ECM to stimulate the proliferation and mobility of vascular
epithelial cells, closely linked to invasion and metastasis of
malignancies (Rundhaug, 2005; Ueda et al, 2005).
The search for MMP-inducing factors in tumour cells leads to
the identification of extracellular MMP inducer (EMMPRIN),
whose name reflects its EMMPRIN activity. Structurally, EMM-
PRIN is a highly glycosylated (HG) cell surface transmembrane
protein which belongs to the immunoglobulin superfamily, and is
composed of two immunoglobulin domains in the extracellular
region, a single transmembrane domain and a short cytoplasmic
domain containing 39 amino acids (Muramatsu and Miyauchi,
2003; Gabison et al, 2005a, b). Cotransfection of EMMPRIN
expression vectors with different tags and crosslinking experi-
ments have suggested that the molecules could associate with each
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sother on the plasma membrane, forming homo-oligomers in a cis-
dependent manner via the N-terminally located Ig-like domain
(Yoshida et al, 2000; Sun and Hemler, 2001). Although EMMPRIN
has a broader tissue distribution and is expressed on activated T
cells, on differentiated macrophage, on retinal pigment epithelium,
in the endometrium and in normal human keratinocytes, its
expression is often elevated on breast cancers, hepatomas,
oesophageal and cervical squamous cell carcinomas, colorectal
and ovarian carcinomas, which increases tumour invasion by
inducing MMP synthesis of surrounding stromal cells, including
membrane type 1 and type 2 MMP, and the endogenous activators
of MMP-2 (Davidson et al, 2003; Ishibashi et al, 2004; Marieb et al,
2004; Gabison et al, 2005a, b; Li et al, 2005; Tang et al, 2005; Zhou
et al, 2005; Sier et al, 2006; van der Jagt et al, 2006). Recently,
various in vivo evidences indicated that EMMPRIN might
stimulate tumour angiogenesis by elevating VEGF and MMP
expression in the neighbouring fibroblasts and epithelial cells in a
paracrine manner (Tang et al, 2005). Taken together, it was
believed that EMMPRIN had strong impact on the invasion and
metastasis of malignant tumours.
Gastric carcinoma ranks the world’s second leading cause of
cancer mortality behind lung cancer despite a sharp worldwide
decline in both its incidence and mortality since the second half of
the 20th century (Kelley and Duggan, 2003). Tumorigenesis and
progression of gastric carcinoma is a multistage process with the
involvement of a multifactorial aetiology, which mainly results
from gene–environment interactions. In our study, EMMPRIN
expression was for the first time examined in gastric carcinoma
and non-cancerous mucosa adjacent to carcinoma (NCMAC), and
compared with its clinicopathological parameters of tumours,
including expression of ki-67, MMP-2, MMP-9 and VEGF proteins
as well as prognosis to explore the roles of EMMPRIN in stepwise
development of gastric carcinoma.
MATERIALS AND METHODS
Subjects
Gastric carcinomas (n¼234) and NCMACs (n¼85, 38 cases of
normal mucosa and 47 cases of hyperplastic or metaplastic
mucosa) were collected from our affiliated hospital and related
institutes between 1993 and 2002. The patients with gastric
carcinoma were 170 men and 64 women (38–88 years, mean¼66.8
years). Among them, 104 cases have tumours accompanied with
lymph node metastasis. None of the patients underwent chemo-
therapy or radiotherapy before surgery. They all provided consent
for use of tumour tissue for clinical research and our University
Ethical Committee approved the research protocol. We followed
up carcinoma patients by consulting their case documents and
telephoning.
Pathology
All tissues were fixed in 4% neutralised formaldehyde, embedded
in paraffin and incised into 4mm sections. These sections were
stained by haematoxylin and eosin (HE) to confirm their
histological diagnosis and other microscopic characteristics. The
staging for each gastric carcinoma was evaluated according to the
Union Internationale Contre le Cancer (UICC) system for the
extent of tumour spread (Sobin and Wittekind, 2002). Further-
more, tumour size, depth of invasion, lymphatic and venous
invasion, and differentiation were determined.
Tissue microarray
Representative areas of solid tumours were identified in HE-
stained sections of the selected tumour cases and a 2mm-
in-diameter tissue core per donor block was punched out and
transferred to a recipient block with a maximum of 48 cores using
a Tissue Microarrayer (AZUMAYA KIN-1, Japan). Four-mm-thick
sections were consecutively incised from the recipient block and
transferred to poly-lysine-coated glass slides. Haematoxylin and
eosin staining was performed on tissue microarray for confirma-
tion of tumour tissue (Figure 1).
Cell lines and culture
Gastric carcinoma cell lines, HGC-27 (undifferentiated adeno-
carcinoma), MKN28 (well-differentiated adenocarcinoma) and
MNK45 (poorly differentiated adenocarcinoma), come from
Japanese Physical and Chemical Institute. They were maintained
in RPMI 1640 (MKN28 and MKN45) or MEM (HGC-27) medium
supplemented with 10% foetal bovine serum, 100Uml
 1 penicillin
and 100mgml
 1 streptomycin, in a humidified atmosphere of 5%
CO2 at 371C. Total protein was prepared from all cells by cell
disruption buffer according to PARIS manual (Ambion Inc,
Austin, Texas, USA). All cells were collected by centrifugation,
rinsed with phosphate-buffered saline, fixed by 10% formalin and
then embedded in paraffin.
Immunohistochemistry
Consecutive sections were deparaffinised with xylene, dehydrated
with alcohol and subjected to antigen retrieval by irradiating in
target retrieval solution (TRS, Dako, Carpinteria, CA 93013, USA)
for 5min with microwave oven (Oriental rotor Lmt. Co. Japan).
Five per cent bovine serum albumin was then applied for 1min to
prevent nonspecific binding. The sections were incubated with
primary antibodies for 15min, then treated with the anti-mouse or
anti-rabbit Envison-PO (Dako, USA) antibodies for 15min. All the
incubations were performed in a microwave oven to allow
intermittent irradiation as described previously (Kumada et al,
2004). After each treatment, the slides were washed with TBST
(10mM Tris-HCl, 150mM NaCl, 0.1% Tween 20) three times for
1min. Mouse anti-EMMPRIN (Novocastro, New Castle upon Tyne
NE 1282W, UK; 1:50), rabbit anti-ki-67 (Dako, USA; 1:25), mouse
anti-MMP-2 (Daiichi Fine Chemical. Co. Lt, Japan; 1:50), mouse
anti-MMP-9 (Daiichi Fine Chemical. Co. Lt, Japan; 1:150), rabbit
anti-VEGF (LAB VISION, Fremont CA 94530, USA; ready to use),
and mouse anti-CD34 (Dako, USA; 1:100) antibodies were
employed for the detection of the respective proteins. Binding
sites were visualised with 3,30-diaminobenzidine. After counter-
stained with Mayer’s haematoxylin, the sections were dehydrated,
cleared and mounted. Omission of the primary antibody was used
as a negative control and appropriate positive controls were
utilised as recommended by the manufacturers.
Evaluation of immunohistochemistry
The immunoreactivity to EMMPRIN was localised in the
cytoplasm and membrane, ki-67 in the nucleus, and MMP-2,
Figure 1 Haematoxylin and eosin staining on the tissue microarray of
gastric carcinoma.
EMMPRIN in gastric carcinomas
H-C Zheng et al
1372
British Journal of Cancer (2006) 95(10), 1371–1378 & 2006 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sMMP-9 and VEGF only in the cytoplasm (Figure 2). One hundred
cells were randomly selected and counted from five representative
fields of each section blindly by three independent observers
(Takano Y, Tsuneyama K and Zheng HC). The positive percentage
of counted cells was graded semiquantitatively according to a four-
tier scoring system: negative ( ), 0B5%; weakly positive (þ),
6B25%; moderately positive (þþ), 26B50% and strongly
positive (þþþ), 51B100%.
Microvessel density counting
CD34 expression in the cytoplasm and membrane of vascular
epithelial cells was selected for the microvessel density (MVD)
counting, although it was occasionally localised in tumour cells
and fibroblasts. A modified Weidner’s method was used to
calculate the MVD of gastric carcinoma after anti-CD34 immuno-
staining (Weidner, 1995). In brief, observers selected five
representative areas and counted individual microvessels on a
 400 field (0.1885mm
2 per field) after the area of highest
neovascularisation was identified, Any brown staining endothelial
cell or endothelial cell cluster that was clearly separated from the
adjacent microvessel, tumour cells and other connective tissue
elements was considered as a single, countable microvessel. The
counts were performed independently by two investigators.
Western blot
Fifty micrograms of denatured protein was separated on an SDS–
polycrylamide gel (10% acrylamide) and transferred to Hybond
membrane (Amersham, Germany), which was then blocked
overnight in 5% milk in TBST. For immunobloting, the membrane
was incubated for 1h with the antibody against EMMPRIN
(Novocastra, UK, 1:100). Then, it was rinsed by TTBS and
incubated with anti-mouse IgG conjugated to horseradish
peroxidase (Dako, USA, 1:1000) for 1h. Bands were visualised
with X-ray film (Fujifilm, Japan) by Amersham ECL-Plus detection
reagents (Amersham, Germany). After that, membrane was washed
with WB Stripping Solution (pH2-3, Nacalai, Japan) for 1h and
treated as described above, except mouse tubulin-a antibody
(Dako, USA, 1:100) as internal control.
Statistical analysis
Statistical evaluation was performed using Spearman correlation
test to analyse the rank data and Kruskal–wallis H test to
differentiate non-parametric means of different groups. Kaplan–
Meier survival plots were generated and comparisons between
survival curves were made with the log-rank statistic. The Cox’s
proportional hazard model was employed for multivariate analysis.
Po0.05 was considered as statistically significant. SPSS 10.0
software was employed to analyse all data.
RESULTS
Extracellular MMP inducer expression in gastric
carcinomas
Extracellular MMP inducer expression was evident in the
cytoplasm and membrane of hyperplastic, metaplastic epithelial
cells of NCMAC and cancerous cells of stomach (Figure 2A, B). As
showed in Table 1, EMMPRIN expression was increased from
gastric normal mucosa to carcinoma through hyperplastic or
metaplastic mucosa (Po0.05). As summarised in Table 2,
EMMPRIN expression showed a significantly positive association
with tumour size, depth of invasion, lymphatic invasion, expres-
sion of ki-67, MMP-2, MMP-9 and VEGF of tumours (Po0.05), but
not with lymph node metastasis, UICC staging or differentiation
(P40.05). Interestingly, there was a significantly positive relation-
ship between EMMPRIN expression and MVD in the gastric
carcinomas (Po0.05) (Table 3).
Figure 2 Immunostaining in gastric carcinoma and non-cancerous mucosa. Note EMMPRIN expression limited to cytoplasm and membrane in
hyperplastic (A) and metaplastic (B) NCMAC and carcinoma (C, D) of the stomach. Ki-67 (E) distributed to the nucleus of gastric carcinoma cells, MMP-2
(F), MMP-9 (G) and VEGF (H) to the cytoplasm, and CD34 (I) in the membrane and cytoplasm of vascular epithelial cell to label MVD.
EMMPRIN in gastric carcinomas
H-C Zheng et al
1373
British Journal of Cancer (2006) 95(10), 1371–1378 & 2006 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
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EMMPRIN expression
Groups n   + ++ +++ PR (%) rs P-value
Normal mucosa 38 26 10 2 0 31.6 0.288 o0.0001
Hyperplastic or metaplastic mucosa 47 17 20 9 1 63.8
Carcinoma 234 82 51 47 54 65.0*
EMMPRIN¼extracellular matrix metalloproteinase inducer; NCMAC¼non-cancerous mucosa adjacent to carcinoma; PR¼positive rate; rs¼Spearmen correlation coefficient.
Table 2 Relationship between EMMPRIN expression and clinicopathological features of gastric carcinoma
EMMPRIN expression
Clinicopathological features n   + ++ +++ PR (%) rs P-value
Tumour size (cm) 0.154 o0.05
o4cm 110 44 27 21 18 60.0
X4cm 124 38 24 26 36 69.4
Depth of invasion 0.142 o0.05
Tis–T1 113 41 34 21 17 63.7
T2–T4 121 41 17 26 37 66.1
Lymphatic invasion 0.129 o0.05
  140 51 39 24 26 63.6
+ 94 31 12 23 28 67.0
Venous invasion 0.298 o0.001
  206 78 49 41 37 62.1
+ 28 3 2 6 17 89.3
Lymph node metastasis 0.094 40.05
  130 48 33 23 26 63.1
+ 104 34 18 24 28 67.3
UICC staging 0.106 40.05
O–I 141 52 36 25 28 63.1
II–IV 93 30 15 22 26 67.7
Differentiation 0.067 40.05
Well 94 26 25 27 16 72.3
Moderate 30 10 5 4 11 66.7
Poor 110 46 21 16 27 58.2
Ki-67 expression 0.184 o0.005
  18 10 2 3 3 44.4
+ 34 14 7 7 6 58.8
++ 57 25 11 11 10 56.1
+++ 125 33 31 26 35 73.6
MMP-2 expression 7.484 o0.001
  21 13 5 2 1 38.1
+ 36 16 13 5 2 55.6
++ 72 30 18 12 12 58.3
+++ 90 16 12 26 36 82.2
MMP-9 expression 0.378 o0.001
  65 34 13 9 9 47.7
+ 31 15 8 5 3 51.6
++ 51 22 10 12 7 56.9
+++ 81 9 20 20 32 88.9
VEGF expression 0.431 o0.001
  47 31 12 2 2 34.0
+ 42 15 13 11 3 64.3
++ 37 15 7 9 6 59.5
+++ 103 21 19 24 39 79.6
EMMPRIN¼extracellular matrix metalloproteinase inducer; PR¼positive rate; MMP¼matrix metalloproteinase; rs: Spearmen correlation coefficient; Tis¼carcinoma in situ;
T1¼lamina propria and submucosa; T2¼muscularis propria and subserosa; T3¼exposure to serosa; T4¼invasion into serosa; UICC¼Union Internationale Contre le Cancer;
VEGF¼vascular endothelial growth factor.
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according to immunostaining data (Figure 3). Extracellular MMP
inducer exists in tumour and transformed cell lines as HG form
migrating at B45–65kDa and as a less glycosylated (LG) form
migrating at B32–44kDa, depending on the glycosylation of the
core protein (27kDa) (Riethdorf et al, 2006; Vigneswaran et al,
2006). Western blot also indicated these cell lines strongly
expressed EMMPRIN, but the HG form in all cell lines and LG
one strongly in HGC-27 and MKN45 and weakly in MKN28
(Figure 4).
Univariate and multivariate survival analysis
Follow-up information was available on 219 patients with gastric
carcinoma for period ranging from 0.2 months to 12.2 years
(mean¼40.4 months). Figure 5 showed the survival curves
stratified according to EMMPRIN expression. Univariate analyses
using Kaplan–Meier method indicated that cumulative rate of the
patients with negative EMMPRIN expression was significantly
higher than that with its weakly, moderately and strongly positive
expression (Po0.05). Multivariate analysis using the Cox’s
proportional hazard model indicated that depth of invasion,
lymphatic and venous invasion, but not EMMPRIN, were
independent prognostic factors (Table 4). Further analysis showed
that these three locally invasive factors to have effects on the
relationship between EMMPRIN expression and survival time of
the carcinoma patients (Table 5).
DISCUSSION
The microenvironment of the tumour–host interface is involved in
many processes impacting on tumour development, including
angiogenesis, growth, dissemination and metastasis of tumours.
The crosstalk interaction between tumour cells and adjacent
stromal cells participates in tumour immune escape, spreading and
angiogenesis, which is conducted by a number of soluble and
membrane molecules, including soluble Fas, Fas ligand, soluble
Table 3 Relationship between EMMPRIN expression and MVD in gastric
carcinoma
EMMPRIN expression n MVD (mean7s.d.) P-value
  82 30.4718.7 o0.05
+ 50 28.6712.6
++ 47 36.1717.9
+++ 54 38.9723.0
Total 233 33.1718.9
EMMPRIN¼extracellular matrix metalloproteinase inducer; MVD¼microvessel
density; s.d., standard deviation.
Figure 3 Extracellular MMP inducer immunostaining in gastric carcinoma cell lines. (A) HGC-27; (B) MKN28; (C) MKN45.
E
M
M
P
R
I
N
Tubulin
kDa
100
75
50
37
25
HG
LG
1 2                  3

Figure 4 Western blot analysis of EMMPRIN in gastric carcinoma cell
lines. Cell lysate was loaded and probed with monoclonal mouse anti-
human EMMPRIN antibody with tubulin-a as an internal control. Lane no. 1:
HGC-27; no. 2 MKN28; no. 3 MKN45. HG: highly glycosylated form
(B45–65kDa); LG: less glycosylated form (B32–44kDa).
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Figure 5 Correlation between status of EMMRIN and prognosis of the
gastric carcinoma patients. Kaplan–Meier curves for cumulative survival rate
of patients with gastric carcinomas according to EMMPRIN expression.
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et al, 2005).
Numerous studies have indicated that the presence and
modulation of EMMPRIN might play some role in the normal
physiological processes (Gabison et al, 2005a, b). In the present
study, it was found that EMMPRIN was positively expressed in
hyperplastic or metaplastic epithelium of gastric NCMAC. Gabison
et al (2005a, b) also reported EMMPRIN to be predominantly
expressed in corneal epithelium but markedly elevated in the
anterior stroma of ulcerated corneas. Therefore, we speculate that
EMMPRIN might be involved in stromal remodelling and
epithelial repair after injury. Compared with gastric normal,
hyperplastic or metaplastic mucosa, gastric carcinoma highly
expressed EMMPRIN protein in line with other malignancies
(Davidson et al, 2003; Ishibashi et al, 2004; Marieb et al, 2004; Li
et al, 2005; Tang et al, 2005; Zhou et al, 2005; Sier et al, 2006; van
der Jagt et al, 2006). Additionally, strong expression was also
observed in gastric carcinoma cell lines in our study. Experimental
overexpression of EMMPRIN in relatively less aggressive carcinoma
cells lines results in an ability to form large and malignant tumours
with a more invasive phenotype in the nude mice (Toole, 2003).
These findings suggest that upregulation of EMMPRIN plays an
essential role in the malignant transformation of gastric epithelial
cells.
Elevated EMMPRIN expression has also been shown to correlate
with the progression of various malignancies (Davidson et al, 2003;
Ishibashi et al, 2004; Marieb et al, 2004; Gabison et al, 2005a, b; Li
et al, 2005; Tang et al, 2005; Zhou et al, 2005; Sier et al, 2006; van
der Jagt et al, 2006). Our results indicated that EMMPRIN
overexpression was positively linked to tumour size of gastric
carcinoma. To explore the mechanism about the regulatory effect
of EMMPIN on tumour growth, we examined expression of ki-67, a
good proliferation marker and consequently found a positive
association between the two parameters. Yang et al (2006) found
that EMMPRIN expression in breast carcinoma cells rendered
them resistant to anoikis, a form of apoptosis triggered by a lack of
or improper cell-matrix interactions, mediated by downregulation
of the proapoptotic BH3-only protein, Bim, through an MAP
kinase-dependent pathway. Marieb et al (2004) documented that
upregulated EMMPRIN expression stimulates hyaluronan produc-
tion by elevating hyoluronan synthases, which is closely related to
the anchorage-independent growth of cancer cells. Taken together,
our result supported the opinion that EMMPRIN might enhance
tumour growth of gastric carcinomas by disrupting the balance
between apoptosis and proliferation.
Our results showed no association between EMMPRIN expres-
sion and carcinoma differentiation, although its higher expression
was found in intestinal-type gastric carcinoma (Zheng et al, 2006a,
b). The discrepancies might be largely attributable to different
grouping and statistical methods. For example, the Spearman
correlation analysis was employed to analyse the rank data in the
present study, which could differentiate not only positive rate but
also expression level. It was worth noting that LG EMMPRIN was
weaker in the well-differentiated cell line (MKN28) than the poorly
differentiated (MNK45) or undifferentiated ones (HGC-27),
although there was no difference in its expression level from our
statistical results of immunohistochemistry in gastric carcinoma,
indicating that EMMPRIN glycosylation might be linked to
carcinoma differentiation.
In our study, it was found that gastric carcinomas with higher
EMMPRIN expression displayed more ability to invade into
lymphatic or venous vessels, or through the gastric wall. A large
body of evidence indicates that increased soluble EMMPRIN
released from cancer cells can stimulate the MMP synthesis and
activation of surrounding stromal cells so as to promote the
progression of tumours (Yoshida et al, 2000; Sun and Hemler,
2001; Davidson et al, 2003; Muramatsu and Miyauchi, 2003;
Ishibashi et al, 2004; Marieb et al, 2004; Gabison et al, 2005a, b; Li
et al, 2005; Tang et al, 2005; Zhou et al, 2005; Sier et al, 2006; van
der Jagt et al, 2006). Recently, Tang et al (2004) indicated that
elevation of MMPs mediated by EMMPRIN could result in more
proteolytic cleavage of membrane-associated EMMPRIN, forming
a positive feedback tumour-stoma interaction. Furthermore,
EMMPRIN transfection of tumour cells or treating tumour cells
with the recombinant protein increased the expression of MMPs,
especially MMP-2 (Sun and Hemler, 2001), as also evidenced by
the positive correlation of EMMPRIN expression with MMP-2 and
MMP-9 expression in our cases of gastric carcinoma. Our group
also found the negative association between expression of
EMMPRIN and ECM tenascin, possibly owing to its regulatory
effect on MMP secretion (Zheng et al, 2006a, b). It was suggested
Table 4 Multivariate analysis of clinical variables for gastric carcinomas
Number Clinicopathological parameters Relative risk (95% CI) P-value
A Tumour size (X4cm) 1.496 (0.792–2.826) 40.05
B Depth of invasion (Tis,1/T2,3) 3.635 (1.501–8.804) o0.05
C Lymphatic invasion ( /+) 1.576 (1.222–2.032) o0.05
D Venous invasion ( /+) 1.539 (1.068–2.218) o0.05
E Lymph node metastasis ( /+) 2.635 (0.913–7.607) 40.05
F UICC staging (O–I/II–IV) 0.429 (0.143–1.284) 40.05
G Differentiation (Well/moderately/poorly) 1.014 (0.778–1.322) 40.05
H Ki-67 expression ( /+/++/++++) 0.822 (0.619–1.092) 40.05
I MMP-2 expression ( /+/++/++++) 0.978 (0.706–1.357) 40.05
J MMP-9 expression ( /+/++/++++) 1.028 (0.836–1.264) 40.05
K VEGF expression ( /+/++/++++) 0.957 (0.748–1.225) 40.05
L MVD 1.001 (0.987–1.014) 40.05
M EMMPRIN expression ( /+B++++) 1.055 (0.848–1.313) 40.05
CI¼confidence interval; EMMPRIN¼extracellular matrix metalloproteinase inducer; MMP¼matrix metalloproteinase; MVD¼microvessel density; UICC¼Union
Internationale Contre le Cancer; VEGF¼vascular endothelial growth factor.
Table 5 Multivariate analysis of EMMPRIN expression and other
concordant factors in gastric carcinomas
Groups Relative risk (95%CI) P-value
M 1.191 (0.917–1.415) o0.05
M+B 1.085 (0.917–1.285) 40.05
M+C 1.084 (0.912–1.290) 40.05
M+D 1.042 (0.860–1.263) 40.05
M+B+C 1.052 (0.887–1.248) 40.05
M+B+D 0.990 (0.820–1.195) 40.05
M+C+D 1.008 (0.837–1.214) 40.05
M+B+C+D 0.982 (0.816–1.181) 40.05
CI¼confidence interval; EMMPRIN¼extracellular matrix metalloproteinase inducer.
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sthat upregulated EMMPRIN expression possibly contributes to
local invasion by stimulating the MMP expressions of both stromal
and tumour cells in gastric carcinomas.
Tumour growth depends not only on apoptotic suppression, but
also angiogenesis. In the present study, we found that there was a
positive relationship between EMMPRIN expression and MVD in
gastric carcinoma. A recent study indicated that EMMPRIN could
enhance VEGF expression of stromal fibroblasts and carcinoma
cells to stimulate tumour angiogenesis via the PI3K-Akt signalling
pathway (Tang et al, 2005, 2006). Our results also showed that
EMMPRIN expression was positively correlated with VEGF
expression in gastric carcinoma. The EMMPRIN-induced MMP
expression in cancer cells also had impact on the tumour
angiogenesis (Sun and Hemler, 2001). In combination of these
evidences, it was suggested that EMMPRIN-mediated angiogenesis
might participate in growth and spread of gastric carcinoma.
Although Ishibashi et al (2004) reported that EMMPRIN
expression was not associated with the recurrence-free survival
of oesophageal squamous cell carcinoma, Davidson et al (2003)
found that EMMPRIN was a good prognostic marker in ovarian
carcinoma. To further clarify the clinicopathological significance,
we analysed the relation of EMMPRIN expression with survival of
219 patients with gastric carcinoma. The results revealed a link
between loss and favourable survival, albeit not independent of
other parameters. The multivariate analysis demonstrated three
independent prognostic factors, depth of invasion, lymphatic and
venous invasion, which affected the relationship between EMM-
PRIN expression and prognosis.
In conclusion, upregulated expression of EMMPRIN might
contribute to tumorigenesis, growth and local invasion of gastric
carcinoma. Altered EMMPRIN expression might enhance invasion
and angiogenesis via upregulating MMP and VEGF expression of
both stromal fibroblasts or gastric carcinoma cells. It could thus be
considered as an objective and effective marker to predict the
invasion and prognosis of gastric carcinoma. The regulatory effects
of EMMPRIN on VEGF in gastric carcinoma should be clarified in
the further study.
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